Blogs

Be the first person to recommend this.
The National Uniform Billing Committee (NUBC) finalized a series of new codes on inpatient claims for cell and gene therapies, thanks in part to the leadership of ASBMT. These changes are expected to go live on April 1, 2019. The changes may assist with improved provider reimbursement over time, which may decrease payment-related access barriers. Junga Shah and Valerie Rinkle, from Nimitt Consulting, advocated for this change on behalf of ASBMT. In a letter submitted to Centers for Medicare and Medicaid Services (CMS) in November 2017, ASBMT outlined a detailed scope of the changes that would need to be made by NUBC on this issue. The Society was then ...
0 comments
Be the first person to recommend this.
Abstract submission for the TCT Meetings of ASBMT & CIBMTR (Houston, TX, February 20-24, 2019) is open through October 12, 2018. Please submit your abstract and you may have the opportunity to present your research and ideas to colleagues from around the world. For more details, a list of topics, and instructions on how to submit your work, please click here .
0 comments
Be the first person to recommend this.
The ASBMT Pharmacy SIG Education Committee is excited to share the development of an Online Journal Club. The goal of these journal clubs will be to provide education and more in-depth review of literature related to the field of stem cell transplantation and cellular therapy and will be provided a few times a year. The first online journal club will be Wednesday October 10 th , from 3-4 PM CST  and will be presented by Dr. Cameron Ninos who will highlight an in-depth review regarding the article “ Shortened-duration Tacrolimus after nonmyeloablative, HLA-haploidentical bone marrow transplantation ”.  We hope you can join us for this exciting new initiative. ...
0 comments
Be the first person to recommend this.
By ASBMT President John F. DiPersio, MD, PhD There’s something really special about being part of a community like ASBMT. Not only do we create strong friendships with our colleagues, we get the chance to share with one another the incredible things we’re doing. Our organization is made up of several different types of professionals. From researchers to clinicians, we all bring something unique to the table. Which is why I was delighted to attend ASBMT’s CEC meeting in Nashville on Sept. 20. The CEC was phenomenally well attended.  The talks covered many aspects of transplant and cellular therapy treatments and were well received by all.  The faculty ...
0 comments
Be the first person to recommend this.
By Mikaela VanMoorleghem, Education and Training Coordinator, Foundation for the Accreditation of Cellular Therapy WMDA-NetCord & FACT Event at Inaugural Cord Blood Connect International Congress Was a Success! The WMDA and FACT co-hosted a cord blood day at the 2018 Cord Blood Connect International Congress in Miami, Florida. Over 50 members of the cord blood community from fourteen countries, joined the WMDA and FACT on September 14, 2018, for a cord blood workshop day. The day included major topics such as global perspectives of cord blood transplants, ethical dilemmas in cord blood banking, common FACT-NetCord accreditation citations, and ...
0 comments
Be the first person to recommend this.
Host Genetics May Affect aGVHD Risk Rashidi A, Shanley R, Yohe SL, et al. Recipient Single Nucleotide Polymorphisms in Paneth Cell Antimicrobial Peptide Genes and Acute Graft-Versus-Host Disease. British Journal of Haematology. 2018; 182 (6): 887 (doi: 10.1111/bjh.15492). New research suggests host genetics may influence acute graft-versus-host disease (aGVHD) risk by modulating Paneth cell function. Knowing that the risk of acute graft-versus-host disease (aGVHD) is influenced by gut dysbiosis and that immune regulation is contributed to by Paneth cell and microbiota interactions, investigators evaluated single nucleotide polymorphisms (SNPs) in the genes ...
0 comments
Be the first person to recommend this.
SCID Genotype and Post-Transplant CD4 Count Predict Survival, Immune Recovery Haddad E, Logan BR, Griffith LM, et al. SCID Genotype and 6-Month Post-Transplant CD4 Count Predict Survival and Immune Recovery. Blood. 2018; (doi: 10.1182/blood-2018-03-840702). This retrospective study conducted by the Primary Immune Deficiency Treatment Consortium showed that among 662 patients with Severe Combined Immunodeficiency (SCID) given a hematopoietic cell transplant (HCT) from 1982-2012 the SCID genotype and the CD4+ and CD4+CD45RA+ cell counts 6 and 12 months post-HCT were predictive of overall survival and long-term T-cell reconstitution. Best survival was observed ...
0 comments
Be the first person to recommend this.
Literature summaries are provided as information only. Please refer to the original published articles for complete details on study methodology, results and discussion.   ***        Must read. Landmark publication that affects practice **           Recommend reading. Secondary paper that adds to literature *             Consider reading. Cursory importance to the practice   Allogeneic Transplant *Johnston EE, Muffly L, Alvarez E, et al. End-of-life care intensity in patients undergoing allogeneic hematopoietic cell transplantation: a population-level analysis. J Clin Oncol . 2018 Sep 5. [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/30183467 ...
0 comments
Be the first person to recommend this.
By the time you are reading this, we will have submitted our last official comment letter of the year to CMS – a feeling that is akin to completing your last exam before summer.  There will be more off-cycle communications between ASBMT and CMS, but those will be driven by a different, more internally controlled process.  For those of you that submitted comments during this busy year – THANK YOU! Those efforts can seem pointless – like sending a postcard into the void – but they really do add up and matter.  We have a host of information to share with you this month, so I won’t drag this out further.  As always, please contact me with any concerns about policy ...
0 comments
Be the first person to recommend this.
On August 30, ASBMT had the privilege of meeting with Seema Verma, Administrator for the Centers of Medicare and Medicaid Services (CMS). She met with several ASBMT leaders—including President John DiPersio, Executive Director Andre Williams, and Director of Health Policy & Strategic Relations Stephanie Farnia—to discuss Medicare inpatient final rule for CAR-T therapies. In late August, the CMS put forward a new payment scheme that categorizes CAR-T therapies under Medicare Severity-Diagnosis Related Groups. With the new rule, the use of these therapies will have a maximum threshold of $186,500 per case, starting in 2019. While many regard this as an ...
0 comments
Be the first person to recommend this.
Literature summaries are provided as information only. Please refer to the original published articles for complete details on study methodology, results and discussion. ***        Must read. Landmark publication that affects practice **           Recommend reading. Secondary paper that adds to literature *             Consider reading. Cursory importance to the practice Graft Versus Host Disease **Nygaard M, Andersen NS, Moser CE, et al. Evaluation of infliximab as second-line treatment of acute graft versus host disease – validating response on day 7 and 28 as predictors of survival.  Bone Marrow Transplant. 2018;53:844-851. https://www.ncbi.nlm.nih.gov/pubmed/29391524 ...
0 comments
Be the first person to recommend this.
On behalf of the ASBMT Committee on Education, we are pleased to continue our monthly self-directed learning quiz "Basic Principles and Practices of Hematopoietic Cell Transplantation and Cell Therapy – Question and Answer Approach” for fellows in training, highlighting HCT and cell therapy topics. Answers to each question appear with evidence-based “non-exhaustive peer-review commentary. Our aim is to provide you with a credible and freely available educational resource. Questions were generated and reviewed by Syed Abutalib, M.D., Mark R. Litzow, M.D., and William A. Wood, M.D. To take this month’s quiz,  click here .
0 comments
Be the first person to recommend this.
By Mikaela VanMoorleghem, FACT education and training coordinator Data Management Resources Serve as Gateway to Improving Reporting To assess compliance with FACT standard B9, the FACT-CIBMTR Data Audit Committee reviews each program’s most recent CIBMTR data audit results including implementation, adequacy, and effectiveness of the corrective action plan (CAP). The committee’s goal is to provide education and assistance to cellular therapy programs throughout the accreditation cycle to achieve quality improvement in data management. At the time of accreditation renewal, the FACT Accreditation Committee assesses the completeness and accuracy of a program’s ...
0 comments
Be the first person to recommend this.
By Dr. John F. DiPersio, ASBMT President The season of fall marks so many things: the holidays are around the corner, school is in session, football is back and the year is coming to a close. While it still seems light-years away, 2019 is slowly creeping up on us. And there’s no better time than fall to get a head start and go into the New Year strong. Just as the leaves change, so has the field of cellular transplantation. In the past 20 years, we’ve seen incredible advances in technology and knowledge that have led to people living better lives. Years ago—before our organization was established—most of us in the field didn’t communicate the way we do now. ...
0 comments
Be the first person to recommend this.
By Dr. Linda Burns, National Marrow Donor Program/Be The Match Our profession has long been committed to enhancing the quality of care for patients in need of a potentially life-saving hematopoietic cell transplant (HCT). Increasingly, there is a recognition that the quality of care depends on a healthy work force. Burnout, a syndrome of depersonalization (feeling of cynicism), emotional exhaustion, and low personal accomplishment adversely affects the well-being of providers and the quality of care provided. As HCT providers frequently care for very ill patients, moral distress that occurs when a provider is unable to provide the care perceived to be best ...
0 comments
Be the first person to recommend this.
Interactions between leukemic niche and HSPCs identify a novel signaling axis Wu  L,  Amarachintha  S , Xu  J, et al. Mesenchymal COX2-PG Secretome Engages NR4A-WNT Signalling Axis in Haematopoietic Progenitors to Suppress Anti-Leukaemia Immunity. British Journal of Haematology. 2018 on-line library doi: 10.1111/bjh.15548. Study results suggest that specific interactions between leukaemic mesenchymal niche and haematopoietic stem and progenitor cells (HSPCs) orchestrate a unique COX2/PG-NR4A/WNT signaling axis, connecting inflammation, cellular metabolism, and cancer immunity. Researchers studied the interaction between leukaemic mesenchymal niche and ...
0 comments
Be the first person to recommend this.
Both MAC and RIC are valid options for PTCy-Haploidentical PBSC Transplantation Sugita J, Kagaya Y, Miyamoto  T  et al.  Myeloablative and reduced-intensity conditioning in HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Using Post-Transplant Cyclophosphamide. Bone Marrow Transplantation: published online 08/07/18  (doi: 10.1038/s41409-018-0279-1). Investigators found that myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) both represent safe and effective choices for HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide (PTCY-haploPBSCT). The finding applies to adults ...
0 comments
Be the first person to recommend this.
By Stephanie Farnia, ASBMT Director of Health Policy and Strategic Relations September is the time of the year where the Medicare rule season starts to wind down (hurray!) and we have a window of time to work on other efforts – coverage, coding and educational efforts being among them. This is a welcome change from the focus on scribing comment letters and a good time to reassess priorities before the end of the calendar year. 2018 has largely been the year of CAR-T on the health policy side, simply due to the frequency of new issues cropping up and the dollars at stake for the membership and your associated facilities. I am not anticipating a natural slowing ...
0 comments
Be the first person to recommend this.
In this month's Pharmacy SIG literature update: Third auto, K-Mel conditioning and transplant in the setting renal impairment for patients with multiple myeloma. Plus, how does ideal versus total body weight dosing impact busulfan PK? As well as real-world use of defibrotide, reviews of EBV/PTLD and more! Literature summaries are provided as information only. Please refer to the original published articles for complete details on study methodology, results and discussion.   ***        Must read. Landmark publication that affects practice **           Recommend reading. Secondary paper that adds to literature *             Consider reading. Cursory ...
0 comments
Be the first person to recommend this.
On behalf of the ASBMT Committee on Education, we are pleased to continue our monthly self-directed learning quiz "Basic Principles and Practices of Hematopoietic Cell Transplantation and Cell Therapy – Question and Answer Approach” for fellows in training, highlighting HCT and cell therapy topics. Answers to each question appear with evidence-based “non-exhaustive peer-review commentary. Our aim is to provide you with a credible and freely available educational resource. Questions were generated and reviewed by Syed Abutalib, M.D., Mark R. Litzow, M.D., and William A. Wood, M.D. To take this month’s quiz, click he
0 comments